On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.
Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.4 billion in the period from 10 August 2009 to 18 December 2009.
Since the announcement as of 31 August 2009, the following transactions have been made under the programme:
Number of Average Transaction shares purchase price value, DKK Accumulated, last announcement 1,125,000 353,840,250 31 August 2009 75,000 317.7100 23,828,250 1 September 2009 75,000 317.5400 23,815,500 2 September 2009 80,000 317.3499 25,387,992 3 September 2009 100,000 313.9550 31,395,500 4 September 2009 66,000 316.1590 20,866,494 Accumulated under the programme 1,521,000 479,133,986
With the transactions stated above, Novo Nordisk owns a total of 26,357,808 treasury shares, corresponding to 4.3% of the share capital. The total amount of shares in the company is 620,000,000 including treasury shares. Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 27,900 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.
SOURCE: Novo Nordisk A/S